A new assay to assess steroid-hormone responsiveness in head and neck cancer

N. J. Berg, H. B. Neel, L. H. Weiland, T. C. Spelsberg

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A new assay has been developed to predict the effectiveness of steroid-hormone therapy in various tumors. The Biopsy Nuclear Binding assay measures the amount of biologically active receptor that binds both steroid hormone and acceptor sites in the nucleus. This assay does not measure the entire receptor population, only those that are biologically active; therefore, it should more accurately predict the response to steroid-hormone therapy. We applied this assay effectively in breast and endometrial carcinoma. Preliminary studies have shown that 40% of patients with head and neck squamous-cell carcinomas have biologically active (nuclear bounds) progesterone receptors. If nuclear binding predicts a remission with hormonal therapy, then the quality of life of appropriately selected patients could greatly improve.

Original languageEnglish (US)
Pages (from-to)286-290
Number of pages5
JournalLaryngoscope
Volume97
Issue number3 I
StatePublished - 1987
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Steroids
Hormones
Progesterone Receptors
Endometrial Neoplasms
Therapeutics
Quality of Life
Breast Neoplasms
Biopsy
Population
Neoplasms

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Berg, N. J., Neel, H. B., Weiland, L. H., & Spelsberg, T. C. (1987). A new assay to assess steroid-hormone responsiveness in head and neck cancer. Laryngoscope, 97(3 I), 286-290.

A new assay to assess steroid-hormone responsiveness in head and neck cancer. / Berg, N. J.; Neel, H. B.; Weiland, L. H.; Spelsberg, T. C.

In: Laryngoscope, Vol. 97, No. 3 I, 1987, p. 286-290.

Research output: Contribution to journalArticle

Berg, NJ, Neel, HB, Weiland, LH & Spelsberg, TC 1987, 'A new assay to assess steroid-hormone responsiveness in head and neck cancer', Laryngoscope, vol. 97, no. 3 I, pp. 286-290.
Berg NJ, Neel HB, Weiland LH, Spelsberg TC. A new assay to assess steroid-hormone responsiveness in head and neck cancer. Laryngoscope. 1987;97(3 I):286-290.
Berg, N. J. ; Neel, H. B. ; Weiland, L. H. ; Spelsberg, T. C. / A new assay to assess steroid-hormone responsiveness in head and neck cancer. In: Laryngoscope. 1987 ; Vol. 97, No. 3 I. pp. 286-290.
@article{59e1161afbb44a2fb5fe5476b2490162,
title = "A new assay to assess steroid-hormone responsiveness in head and neck cancer",
abstract = "A new assay has been developed to predict the effectiveness of steroid-hormone therapy in various tumors. The Biopsy Nuclear Binding assay measures the amount of biologically active receptor that binds both steroid hormone and acceptor sites in the nucleus. This assay does not measure the entire receptor population, only those that are biologically active; therefore, it should more accurately predict the response to steroid-hormone therapy. We applied this assay effectively in breast and endometrial carcinoma. Preliminary studies have shown that 40{\%} of patients with head and neck squamous-cell carcinomas have biologically active (nuclear bounds) progesterone receptors. If nuclear binding predicts a remission with hormonal therapy, then the quality of life of appropriately selected patients could greatly improve.",
author = "Berg, {N. J.} and Neel, {H. B.} and Weiland, {L. H.} and Spelsberg, {T. C.}",
year = "1987",
language = "English (US)",
volume = "97",
pages = "286--290",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "3 I",

}

TY - JOUR

T1 - A new assay to assess steroid-hormone responsiveness in head and neck cancer

AU - Berg, N. J.

AU - Neel, H. B.

AU - Weiland, L. H.

AU - Spelsberg, T. C.

PY - 1987

Y1 - 1987

N2 - A new assay has been developed to predict the effectiveness of steroid-hormone therapy in various tumors. The Biopsy Nuclear Binding assay measures the amount of biologically active receptor that binds both steroid hormone and acceptor sites in the nucleus. This assay does not measure the entire receptor population, only those that are biologically active; therefore, it should more accurately predict the response to steroid-hormone therapy. We applied this assay effectively in breast and endometrial carcinoma. Preliminary studies have shown that 40% of patients with head and neck squamous-cell carcinomas have biologically active (nuclear bounds) progesterone receptors. If nuclear binding predicts a remission with hormonal therapy, then the quality of life of appropriately selected patients could greatly improve.

AB - A new assay has been developed to predict the effectiveness of steroid-hormone therapy in various tumors. The Biopsy Nuclear Binding assay measures the amount of biologically active receptor that binds both steroid hormone and acceptor sites in the nucleus. This assay does not measure the entire receptor population, only those that are biologically active; therefore, it should more accurately predict the response to steroid-hormone therapy. We applied this assay effectively in breast and endometrial carcinoma. Preliminary studies have shown that 40% of patients with head and neck squamous-cell carcinomas have biologically active (nuclear bounds) progesterone receptors. If nuclear binding predicts a remission with hormonal therapy, then the quality of life of appropriately selected patients could greatly improve.

UR - http://www.scopus.com/inward/record.url?scp=0023106698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023106698&partnerID=8YFLogxK

M3 - Article

C2 - 3821347

AN - SCOPUS:0023106698

VL - 97

SP - 286

EP - 290

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 3 I

ER -